EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
Compulsory use of the 7-valent pneumococcal conjugate vaccine in the framework of national pediatric immunization schedules of the developed countries resulted in significant decrease in the prevalence of the pneumococcal infections induced by the vaccinal serotypes. However, a growth in prevalence...
Main Authors: | M. V. Fedoseenko, D. A. Novikova, N. E. Tkachenko, M. I. Broeva, T. A. Grechukha, A. G. Gaivoronskaya, V. V. Chernikov |
---|---|
Format: | Article |
Language: | English |
Published: |
Paediatrician Publishers, LLC
2014-09-01
|
Series: | Pediatričeskaâ Farmakologiâ |
Subjects: | |
Online Access: | https://www.pedpharma.ru/jour/article/view/53 |
Similar Items
-
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
by: Strutton David R, et al.
Published: (2012-08-01) -
Changes in Childhood Pneumonia Hospitalizations by Race and Sex Associated with Pneumococcal Conjugate Vaccines
by: Andrew D. Wiese, et al.
Published: (2016-06-01) -
Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01) -
Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
by: Hyunju Lee, et al.
Published: (2014-02-01) -
Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
by: Starla Hayward, et al.
Published: (2016-04-01)